Orlistat and Antisense-miRNA-loaded PLGA-PEG Nanoparticles for Enhanced Triple Negative Breast Cancer Therapy

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2016 Jan 21

PMID 26787319

Citations 31

Authors

Aarohi Bhargava-Shah

Kira Foygel

Rammohan Devulapally

Ramasamy Paulmurugan

Affiliations

Soon will be listed here.

Abstract

Background: This study explores the use of hydrophilic poly(ethylene glycol)-conjugated poly(lactic-co-glycolic acid) nanoparticles (PLGA-PEG-NPs) as delivery system to improve the antitumor effect of antiobesity drug orlistat for triple-negative breast cancer (TNBC) therapy by improving its bioavailability.

Materials & Methods: PLGA-PEG-NPs were synthesized by emulsion-diffusion-evaporation method, and the experiments were conducted in vitro in MDA-MB-231 and SKBr3 TNBC and normal breast fibroblast cells.

Results: Delivery of orlistat via PLGA-PEG-NPs reduced its IC50 compared with free orlistat. Combined treatment of orlistat-loaded NPs and doxorubicin or antisense-miR-21-loaded NPs significantly enhanced apoptotic effect compared with independent doxorubicin, anti-miR-21-loaded NPs, orlistat-loaded NPs or free orlistat treatments.

Conclusion: We demonstrate that orlistat in combination with antisense-miR-21 or current chemotherapy holds great promise as a novel and versatile treatment agent for TNBC.

Citing Articles

Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer.

Singh D, Haque S, Kim Y, Han I, Yadav D Front Immunol. 2024; 15:1455211.

PMID: 39720730 PMC: 11666570. DOI: 10.3389/fimmu.2024.1455211.

Hypoxia drives CBR4 down-regulation promotes gastroenteropancreatic neuroendocrine tumors via activation mammalian target of rapamycin mediated by fatty acid synthase.

Ye M, Xu L, Lu F, Chen L, Hu C, Chen J J Cell Commun Signal. 2024; 18(3):e12041.

PMID: 39524139 PMC: 11544642. DOI: 10.1002/ccs3.12041.

Precious Cargo: The Role of Polymeric Nanoparticles in the Delivery of Covalent Drugs.

Weissberger D, Stenzel M, Hunter L Molecules. 2024; 29(20).

PMID: 39459317 PMC: 11510600. DOI: 10.3390/molecules29204949.

Application of PLGA in Tumor Immunotherapy.

Wu J, Wang X, Wang Y, Xun Z, Li S Polymers (Basel). 2024; 16(9).

PMID: 38732722 PMC: 11085488. DOI: 10.3390/polym16091253.

Fabrication of Nanocrystals for Enhanced Distribution of a Fatty Acid Synthase Inhibitor (Orlistat) as a Promising Method to Relieve Solid Ehrlich Carcinoma-Induced Hepatic Damage in Mice.

Alamoudi J, El-Masry T, Nasr M, Ibrahim I, Ibrahim H, Saad H Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256929 PMC: 10820129. DOI: 10.3390/ph17010096.

References

Devulapally R, Sekar T, Paulmurugan R . Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells. Mol Pharm. 2015; 12(6):2080-92. PMC: 4687493. DOI: 10.1021/mp500852s. View

von Minckwitz G, Martin M . Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol. 2012; 23 Suppl 6:vi35-9. DOI: 10.1093/annonc/mds193. View

Piyathilake C, Frost A, Manne U, Bell W, Weiss H, Heimburger D . The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol. 2000; 31(9):1068-73. DOI: 10.1053/hupa.2000.9842. View

Haley B, Frenkel E . Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008; 26(1):57-64. DOI: 10.1016/j.urolonc.2007.03.015. View

Smith L, Watson M, OKane S, Drew P, Lind M, Cawkwell L . The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther. 2006; 5(8):2115-20. DOI: 10.1158/1535-7163.MCT-06-0190. View

Ballinger A . Orlistat in the treatment of obesity. Expert Opin Pharmacother. 2001; 1(4):841-7. DOI: 10.1517/14656566.1.4.841. View

Boyle P . Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012; 23 Suppl 6:vi7-12. DOI: 10.1093/annonc/mds187. View

Drew B, Dixon A, Dixon J . Obesity management: update on orlistat. Vasc Health Risk Manag. 2008; 3(6):817-21. PMC: 2350121. View

Devulapally R, Sekar N, Sekar T, Foygel K, Massoud T, Willmann J . Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy. ACS Nano. 2015; 9(3):2290-302. PMC: 4374409. DOI: 10.1021/nn507465d. View

10.

Torchilin V . Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2006; 24(1):1-16. DOI: 10.1007/s11095-006-9132-0. View

11.

Cho K, Wang X, Nie S, Chen Z, Shin D . Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008; 14(5):1310-6. DOI: 10.1158/1078-0432.CCR-07-1441. View

12.

Menendez J, Colomer R, Lupu R . Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?. Med Hypotheses. 2004; 64(2):342-9. DOI: 10.1016/j.mehy.2004.07.022. View

13.

Nemoto T, Terashima S, Kogure M, Hoshino Y, Kusakabe T, Suzuki T . Overexpression of fatty acid synthase in oesophageal squamous cell dysplasia and carcinoma. Pathobiology. 2002; 69(6):297-303. DOI: 10.1159/000064636. View

14.

Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A . Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One. 2013; 8(2):e55910. PMC: 3566108. DOI: 10.1371/journal.pone.0055910. View

15.

Guerciolini R . Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997; 21 Suppl 3:S12-23. View

16.

Menendez J, Vellon L, Lupu R . Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol. 2005; 16(8):1253-67. DOI: 10.1093/annonc/mdi239. View

17.

Joensuu H, Gligorov J . Adjuvant treatments for triple-negative breast cancers. Ann Oncol. 2012; 23 Suppl 6:vi40-5. DOI: 10.1093/annonc/mds194. View

18.

Acharya S, Sahoo S . PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2010; 63(3):170-83. DOI: 10.1016/j.addr.2010.10.008. View

19.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

20.

Devulapally R, Paulmurugan R . Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013; 6(1):40-60. PMC: 3865230. DOI: 10.1002/wnan.1242. View